Abstract
Pharmacogenomics is being increasingly applied to the development of novel oncology drugs. Single nucleotide polymorphism genotyping of known drug-metabolizing and transport genes is used to screen for pharmacokinetic differences in drug exposure, and genome-wide transcription profiling is being widely used to identify expression profiles that can be correlated to pharmacodynamic variables resulting from molecular changes within tumors. Given the relatively low efficacy of most cancer therapies, and the molecular heterogeneity within tumors, pharmacogenomics provides one of the best opportunities for improvements in drug efficacy through effective stratification of patients, and early identification of those individuals most likely to respond effectively to a specific therapeutic approach.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent JM (1996) Use of cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 14:457
Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57
Krynetski EY, Evans WE (1999) Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm Res 16:342
Roses AD (2000) Pharmacogenetics and the practice of medicine. Nature 405:857
Roses AD (2002) Genome-based pharmacogenetics and the pharmaceutical industry. Nat Rev Drug Discov 1:541
Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin JC, Mortimore BJ, Willey DL, Hunt SE, Cole CG, Coggil PC, Rice CM, Ning Z, Rogers J, Bentley DR, Kwok PY, Mardis ER, Yeh RT, Schultz B, Cook L, Davenport R, Dante M, Fulton L, Hillier L, Waterston RH, McPherson JD, Gilman B, Schaffner S, Van Etten WJ, Reich D, Higgins J, Daly MJ, Blumenstiel B, Baldwin J, Stange-Thomann N, Zody MC, Linton L, Lander ES, Altshuler D (2001) A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409:928
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eirmann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783
Van't Veer LJ, Dai H, van de Vivjer MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530
Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, Paul KD (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275:343
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was presented at the 18th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium, "New Strategies for Novel Anticancer Drug Development," 8–9 November 2002, Nagoya, Japan.
Rights and permissions
About this article
Cite this article
Dracopoli, N.C. Pharmacogenomic applications in clinical drug development. Cancer Chemother Pharmacol 52 (Suppl 1), 57–60 (2003). https://doi.org/10.1007/s00280-003-0594-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-003-0594-z